Johnson & Johnson

Synexus exceeds expectations in clinical trial recruitment

Tuesday, October 25, 2011 01:53 PM

Synexus’ Pretoria clinical research center has enrolled more patients than any other site across the world in a type 2 diabetes trial for Janssen Pharmaceuticals.

More... »

Foundation Medicine, Johnson & Johnson collaborate in oncology research

Tuesday, October 25, 2011 01:10 PM

Foundation Medicine has reported a collaboration with Johnson & Johnson Pharmaceutical Research and Development. The collaboration is focused on using Foundation Medicine's comprehensive clinical cancer genomic test to identify potential biomarkers to support J&JPRD oncology clinical development programs. Financial details of the agreement were not disclosed.

More... »

Nevro completes $58 million financing round

Friday, July 22, 2011 10:22 AM

Nevro, a neuromodulation company focused on relief of chronic pain, has completed a $58 million financing round led by new investor Johnson & Johnson Development (JJDC). Existing investors Aberdare Ventures, Accuitive Medical Ventures, Bay City Capital, Mayo Clinic, MPM Capital and Three Arch Partners also participated.

More... »

Valeant buys Johnson & Johnson skincare unit for $345 million

Tuesday, July 19, 2011 12:57 PM

Valeant Pharmaceuticals wants to become the world's biggest player in the skincare sector in about five years, its top executive told Reuters. The company has been signaling its intent with a string of recent mid-sized acquisitions in the highly fragmented but lucrative dermatology sector.

More... »

Gilead to allow generic AIDS drugs through Medicines Patent Pool

Wednesday, July 13, 2011 10:46 AM

Gilead Sciences will allow some of its AIDS drugs to be made by generic manufacturers, potentially increasing their availability in poor countries, particularly in Africa, according to the Associated Press.

More... »

FDA eases rules for Alzheimer’s experiments to speed new treatments for dementia

Tuesday, July 12, 2011 12:35 PM

The FDA is making it easier to test new Alzheimer’s drugs, hoping to speed progress toward new treatments for the mind-robbing disease, according to an Associated Press report.

More... »

Jubilant, Janssen collaborate on neuroscience development

Thursday, June 30, 2011 01:28 PM

A Jubilant Life Sciences subsidiary has formed an alliance to deliver pre-clinical candidates in the neuroscience field to Belgium’s Janssen Pharmaceutica, according to PharmaTimes.

More... »

Gilead and J&J explore combo HIV Treatment

Wednesday, June 29, 2011 10:00 AM

Gilead and Johnson & Johnson's Tibotec subsidiary are joining forces on a combo HIV treatment, according to FierceBiotech. Under a new pact, Gilead will combine its new boosting agent cobicistat with J&J's Prezista, a protease inhibitor. This new therapy follows a well-traveled development path as drug companies advance new HIV drugs that require fewer pills and offer greater potency.

More... »

J&J looking to acquire Synthes

Tuesday, April 19, 2011 11:21 AM

Johnson & Johnson is looking to acquire global medical device manufacturer Synthes in a deal that could be worth around $20 billion as reported in Pharma Times.

More... »

SuperGen and Astex to merge

Friday, April 8, 2011 10:47 AM

U.S.-based SuperGen will merge with the U.K.'s Astex Therapeutics in a deal they say will create "a financially strong international oncology company," according to Pharma Times.

More... »